Press release
Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares should contact the Shareholders Foundation in connection with Lawsuit
The Shareholders Foundation, Inc. announces an update in the lawsuit that is pending for certain investors in Ocugen, Inc.
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) prior to May 2020 and continue to hold any of those NASDAQ: OCGN shares have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On April 1, 2024, Ocugen, Inc. filed a Form with the SEC stating that in connection with the preparation of the financial statements of the Company for the year ended December 31, 2023, it identified certain accounting errors and that as a result, it intends to restate its financial statements for the year ended December 31, 2022 and for each of the first three quarters of 2022 and 2023 in the 2023 Form 10-K, the review and preparation of which is currently ongoing..
On April 11, 2024, an investor in NASDAQ: OCGN shares filed a lawsuit against Ocugen, Inc. over alleged securities laws violations. The plaintiff alleged that the defendants made materially false and/or misleading statements and/or failed to disclose that Ocugen's financial statements from May 8, 2020 to the present were materially misstated, that Ocugen, Inc. did not have adequate internal controls, and that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.
On August 6, 2024, the court appointed a lead plaintiff and lead counsel.
Those who purchased NASDAQ: OCGN shares should contact the Shareholders Foundation, Inc.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares should contact the Shareholders Foundation in connection with Lawsuit here
News-ID: 3671215 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Investors in The Estée Lauder Companies Inc. (NYSE: …
An investigation was announced on behalf of current long-term investors in shares of The Estée Lauder Companies Inc. (NYSE: EL) concerning potential breaches of fiduciary duties by certain directors of The Estée Lauder Companies Inc..
Investors who are current long term investors in The Estée Lauder Companies Inc. (NYSE: EL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a…
Investigation announced for Investors in shares of LuxUrban Hotels Inc. (NASDAQ: …
An investigation was announced for investors in shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) concerning potential breaches of fiduciary duties by certain directors and officers of LuxUrban Hotels Inc.
Investors who are current long term investors in LuxUrban Hotels Inc. (NASDAQ: LUXH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Investors who lost money with shares of Liquidia Corporation (NASDAQ: LQDA) shou …
An investigation was announced over potential securities laws violations by Liquidia Corporation in connection with certain financial statements.
Investors who purchased shares of Liquidia Corporation (NASDAQ: LQDA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Liquidia Corporation (NASDAQ: LQDA) concerning whether a series of statements…
Investors in shares of iRhythm Technologies, Inc. (NASDAQ: IRTC) should contact …
An investigation was announced for current long-term investors in shares of iRhythm Technologies, Inc. (NASDAQ: IRTC) concerning potential breaches of fiduciary duties by certain directors and officers of iRhythm Technologies, Inc..
Investors who are current long term investors in iRhythm Technologies, Inc. (NASDAQ: IRTC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
More Releases for Ocugen
Investigation announced for Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) s …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc.
Investors who are current long term investors in Ocugen, Inc. (NASDAQ: OCGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: OCGN stocks follows a lawsuit filed against Ocugen, Inc. over alleged securities…
Lawsuit filed for Investors in shares of Ocugen, Inc. (NASDAQ: OCGN)
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit over alleged violations of Federal Securities Laws by Ocugen, Inc.
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: August 17, 2021. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a clinical-stage…
Retinitis Pigmentosa (RP) Market 2025 : Ocugen, Inc., ReGenX Biosciences, LLC, S …
Global Retinitis Pigmentosa (RP) Market: Snapshot
Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Proportions of retinal capacity, for example, the electroretinogram, demonstrate that photoreceptor capacity is decreased normally quite before symptomic night visual impairment, visual-field scotomas, or diminished visual sharpness…
Retinitis Pigmentosa (RP) Market | Ocugen, Inc., ReGenX Biosciences, LLC, Sucamp …
Global Retinitis Pigmentosa (RP) Market: Overview
Retinitis Pigmentosa (RP), an inherited retinal condition causing retinal degeneration and visual field loss, is a rare disease. Its initial symptoms are reduced night vision and loss of peripheral vision. It gradually causes blindness. There is no definitive cure for retinitis pigmentosa. Therefore, the market for treating this genetic disorder is vastly untapped. The available therapies apply various approaches such as stem cell therapy and…
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise.
Get Sample Copy of…
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise.
Get Brochure of the…
